Carlos J. Suarez
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Carlos J. Suarez has a total of 153 co-authors. Here are the top co-authors by number of shared publications:
- Anuja Sathe
Division of Oncology, Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA
31 shared publications - Hanlee P. Ji
Division of Oncology, Department of Medicine, Stanford University School of Medicine, Stanford, USA
27 shared publications - George A. Poultsides
Department of Surgery, Stanford University, Stanford, CA, USA
26 shared publications - HoJoon Lee
Division of Oncology Department of Medicine Stanford University School of Medicine 94305 Stanford CA United States
25 shared publications - Andrew Su
Institute for Molecular Bioscience, The University of Queensland, Brisbane, Queensland, Australia
24 shared publications - Billy T. Lau
Division of Oncology, Department of Medicine, Stanford University School of Medicine, Stanford, USA
24 shared publications
Latest Publications
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Tables 1-8 from Colorectal Cancer Metastases in the Liver Establish Immunosuppressive Spatial Networking between Tumor-Associated SPP1+ Macrophages and Fibroblasts
Supplemental Table 1: Antibodies, reporters, imaging order and exposure times used in CODEX imaging. EPCAM, SPP1, CD163 were excluded from downstream analysis due to non-specific staining; Supplemental Table 2: Sequencing metrics for scRNA-seq; Supplemental Table 3: Absolute number of cells detected from each sample per cell lineage; Supplemental Table 4: Differentially expressed genes belonging to respective macrophage clusters compared by site of sample origin. pct.1, pct.2 indicate percentage of cells expressing given gene in the cluster of interest and all other comparison clusters respectively; Supplemental Table 5: Enriched reactome pathways in differentially expressed genes in tumor macrophages; Supplemental Table 6: Gene signatures for Foam cells (Fernandez et.al., 2020, PMID 31591603) and scar-associated macrophages (Ramachandran et. al., 2020, PMID 31597160); Supplemental Table 7: Annotation of differentially expressed genes in CAFs with the components of the matrisome expression program; Supplemental Table 8: Spatial proximity analysis examining whether fibroblasts are more proximal to macrophages than any other cell type.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Tables 1-8 from Colorectal Cancer Metastases in the Liver Establish Immunosuppressive Spatial Networking between Tumor-Associated SPP1+ Macrophages and Fibroblasts
Supplemental Table 1: Antibodies, reporters, imaging order and exposure times used in CODEX imaging. EPCAM, SPP1, CD163 were excluded from downstream analysis due to non-specific staining; Supplemental Table 2: Sequencing metrics for scRNA-seq; Supplemental Table 3: Absolute number of cells detected from each sample per cell lineage; Supplemental Table 4: Differentially expressed genes belonging to respective macrophage clusters compared by site of sample origin. pct.1, pct.2 indicate percentage of cells expressing given gene in the cluster of interest and all other comparison clusters respectively; Supplemental Table 5: Enriched reactome pathways in differentially expressed genes in tumor macrophages; Supplemental Table 6: Gene signatures for Foam cells (Fernandez et.al., 2020, PMID 31591603) and scar-associated macrophages (Ramachandran et. al., 2020, PMID 31597160); Supplemental Table 7: Annotation of differentially expressed genes in CAFs with the components of the matrisome expression program; Supplemental Table 8: Spatial proximity analysis examining whether fibroblasts are more proximal to macrophages than any other cell type.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from Colorectal Cancer Metastases in the Liver Establish Immunosuppressive Spatial Networking between Tumor-Associated SPP1+ Macrophages and Fibroblasts
(A) UMAP representation of dimensionally reduced data following batch-corrected graph-based clustering of all tumor epithelial cells annotated by sample. (B) Heatmap depicting expression of five highest significantly expressed genes (adjusted p-value <0.05) per patient. (C) Heatmap representation of inferred single-cell CNV profiles of all tumors and reference cells. (A-C) Data from seven mCRCs.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from Colorectal Cancer Metastases in the Liver Establish Immunosuppressive Spatial Networking between Tumor-Associated SPP1+ Macrophages and Fibroblasts
(A) UMAP representation of dimensionally reduced data following batch-corrected graph-based clustering of all tumor epithelial cells annotated by sample. (B) Heatmap depicting expression of five highest significantly expressed genes (adjusted p-value <0.05) per patient. (C) Heatmap representation of inferred single-cell CNV profiles of all tumors and reference cells. (A-C) Data from seven mCRCs.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 4 from Colorectal Cancer Metastases in the Liver Establish Immunosuppressive Spatial Networking between Tumor-Associated SPP1+ Macrophages and Fibroblasts
(A) Dot plot depicting expression levels of respective ligands and receptors together with the percentage of cells expressing them. (B) Top 10 percent of interactions inferred between cell types in the TME. Edge weights are proportional to the number of interactions, circle sizes are proportional to the number of cells in each group, edge color represents the cell type as sender. For scale, autocrine interactions in CAFs are 68. (A-B) Data from seven mCRCs and five paired normal liver tissue.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 4 from Colorectal Cancer Metastases in the Liver Establish Immunosuppressive Spatial Networking between Tumor-Associated SPP1+ Macrophages and Fibroblasts
(A) Dot plot depicting expression levels of respective ligands and receptors together with the percentage of cells expressing them. (B) Top 10 percent of interactions inferred between cell types in the TME. Edge weights are proportional to the number of interactions, circle sizes are proportional to the number of cells in each group, edge color represents the cell type as sender. For scale, autocrine interactions in CAFs are 68. (A-B) Data from seven mCRCs and five paired normal liver tissue.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 3 from Colorectal Cancer Metastases in the Liver Establish Immunosuppressive Spatial Networking between Tumor-Associated SPP1+ Macrophages and Fibroblasts
(A) UMAP representation of dimensionally reduced data following batch-corrected graph-based clustering of all lymphocyte lineage cells annotated by cell types. (B) Heatmap depicting average expression of selected genes for each cell type. (C) UMAP representation annotated by condition. (D) Heatmap depicting cell states from CD8 T cells identified using EcoTyper NMF analysis, annotated by condition. (A-D) Data from seven mCRCs, five paired normal liver tissue and two paired PBMCs. (E) Violin plot depicting the expression of cytotoxicity gene signature in normal and tumor CD8 T cells with T-test p-value. Data from seven mCRCs, five paired normal liver tissue.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 3 from Colorectal Cancer Metastases in the Liver Establish Immunosuppressive Spatial Networking between Tumor-Associated SPP1+ Macrophages and Fibroblasts
(A) UMAP representation of dimensionally reduced data following batch-corrected graph-based clustering of all lymphocyte lineage cells annotated by cell types. (B) Heatmap depicting average expression of selected genes for each cell type. (C) UMAP representation annotated by condition. (D) Heatmap depicting cell states from CD8 T cells identified using EcoTyper NMF analysis, annotated by condition. (A-D) Data from seven mCRCs, five paired normal liver tissue and two paired PBMCs. (E) Violin plot depicting the expression of cytotoxicity gene signature in normal and tumor CD8 T cells with T-test p-value. Data from seven mCRCs, five paired normal liver tissue.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 2 from Colorectal Cancer Metastases in the Liver Establish Immunosuppressive Spatial Networking between Tumor-Associated SPP1+ Macrophages and Fibroblasts
Heatmap depicting cell states from monocytes and macrophages identified using Ecotyper NMF analysis, annotated by condition and genes with highest fold change in each state. Data from seven mCRCs, five paired normal liver tissue and two paired PBMCs.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 2 from Colorectal Cancer Metastases in the Liver Establish Immunosuppressive Spatial Networking between Tumor-Associated SPP1+ Macrophages and Fibroblasts
Heatmap depicting cell states from monocytes and macrophages identified using Ecotyper NMF analysis, annotated by condition and genes with highest fold change in each state. Data from seven mCRCs, five paired normal liver tissue and two paired PBMCs.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 5 from Colorectal Cancer Metastases in the Liver Establish Immunosuppressive Spatial Networking between Tumor-Associated SPP1+ Macrophages and Fibroblasts
Graphical representation of cell types identified in CODEX analysis in image data from respective patients.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 5 from Colorectal Cancer Metastases in the Liver Establish Immunosuppressive Spatial Networking between Tumor-Associated SPP1+ Macrophages and Fibroblasts
Graphical representation of cell types identified in CODEX analysis in image data from respective patients.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 6 from Colorectal Cancer Metastases in the Liver Establish Immunosuppressive Spatial Networking between Tumor-Associated SPP1+ Macrophages and Fibroblasts
(A-C) Comparisons with Pearson correlation between (A) proportions of cell lineages in five samples with both scRNA-seq and CODEX data. (B) Average expression of LGALS3 and CD68 in macrophages across all 15 patients. (C) Average expression of COL4A1 and ACTA2 in CAFs across all 15 patients.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 6 from Colorectal Cancer Metastases in the Liver Establish Immunosuppressive Spatial Networking between Tumor-Associated SPP1+ Macrophages and Fibroblasts
(A-C) Comparisons with Pearson correlation between (A) proportions of cell lineages in five samples with both scRNA-seq and CODEX data. (B) Average expression of LGALS3 and CD68 in macrophages across all 15 patients. (C) Average expression of COL4A1 and ACTA2 in CAFs across all 15 patients.
- 1 November 2025
- Published by American Society of Clinical Oncology (ASCO) in JCO Precision Oncology
- Vol. 9 (9) , e2500668
Liposarcoma and Leiomyosarcoma as the First Manifestation of Familial Retinoblastoma: Implications for Genetic Testing and Carrier Surveillance
- 1 November 2025
- Published by American Society of Clinical Oncology (ASCO) in JCO Precision Oncology
- Vol. 9 (9) , e2500668
Liposarcoma and Leiomyosarcoma as the First Manifestation of Familial Retinoblastoma: Implications for Genetic Testing and Carrier Surveillance
- 26 May 2025
- Published by Oxford University Press (OUP) in American Journal of Clinical Pathology
- Vol. 164 (3) , 360-366
Rapid clinical deployment of UBA1 testing in patients with VEXAS syndrome
Objective: VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) is a recently described autoinflammatory syndrome caused by pathogenic variants in UBA1. However, there is a dearth of widely available UBA1 testing aside from large, expensive sequencing studies. Thus, we sought to rapidly develop, validate, and clinically deploy a cost-effective assay for detecting the most common UBA1 variants. Methods: We developed, validated, and implemented a single base extension mass spectrometry assay for detecting pathogenic UBA1 variants at the c.121, c.122, and c.118-1 positions in patients with suspected VEXAS syndrome. Assay performance characteristics were assessed using peripheral blood and bone marrow samples from patients with (n = 8) and without (n = 36) VEXAS. Results: The assay demonstrated a lower limit of detection (LOD) of 10% variant allele fraction for each mutation. The analytical accuracy, sensitivity, and specificity were each demonstrated to be 100% at the LOD, with excellent intra- and interrun reproducibility. Based on literature review of reported UBA1 variants associated with VEXAS, to date, this assay detects the most prevalent variants, with a clinical sensitivity of 97% or more. Conclusions: A cost-effective, mass spectrometry–based assay with high analytical and clinical performance can feasibly be implemented in hospital laboratories for diagnosis of VEXAS syndrome.
- 26 May 2025
- Published by Oxford University Press (OUP) in American Journal of Clinical Pathology
- Vol. 164 (3) , 360-366
Rapid clinical deployment of UBA1 testing in patients with VEXAS syndrome
Objective: VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) is a recently described autoinflammatory syndrome caused by pathogenic variants in UBA1. However, there is a dearth of widely available UBA1 testing aside from large, expensive sequencing studies. Thus, we sought to rapidly develop, validate, and clinically deploy a cost-effective assay for detecting the most common UBA1 variants. Methods: We developed, validated, and implemented a single base extension mass spectrometry assay for detecting pathogenic UBA1 variants at the c.121, c.122, and c.118-1 positions in patients with suspected VEXAS syndrome. Assay performance characteristics were assessed using peripheral blood and bone marrow samples from patients with (n = 8) and without (n = 36) VEXAS. Results: The assay demonstrated a lower limit of detection (LOD) of 10% variant allele fraction for each mutation. The analytical accuracy, sensitivity, and specificity were each demonstrated to be 100% at the LOD, with excellent intra- and interrun reproducibility. Based on literature review of reported UBA1 variants associated with VEXAS, to date, this assay detects the most prevalent variants, with a clinical sensitivity of 97% or more. Conclusions: A cost-effective, mass spectrometry–based assay with high analytical and clinical performance can feasibly be implemented in hospital laboratories for diagnosis of VEXAS syndrome.
- 24 November 2023
- Published by Oxford University Press (OUP) in American Journal of Clinical Pathology
- Vol. 161 (4) , 329-341
Diagnostic impact of RNA-based next-generation sequencing fusion panel for solid tumors: A single-institution experience
Objectives: Gene rearrangements frequently act as oncogenic driver mutations and determine the onset and progression of cancer. RNA-based next-generation sequencing (NGS) is being used with increasing frequency for solid tumors. The purpose of our study is to investigate the feasibility and utility of an RNA-based NGS fusion panel for solid tumors. Methods: We conducted a retrospective, single-institution review of fusion panels requested between May 2022 and March 2023. Demographic, clinical, pathologic, and molecular findings of the patients were reviewed. The utility of the RNA-based NGS fusion panel for the pathologic diagnosis of solid tumors was assessed. Results: Our study included 345 cases, and a fusion event was identified in 24.3% (78/321) of cases. Among the 110 cases submitted for diagnostic purposes, a fusion event was detected in 42.7% (47/110) of cases. The results led to refinement or clarification of the initial diagnosis in 31.9% (15/47) of cases and agreement or support for the initial diagnosis in 59.6% (28/47) of cases. Furthermore, our study indicated that the overall cellularity (tumor and normal tissue) of the tested specimen influences the success of the testing process. Conclusions: In summary, this study demonstrated the feasibility and utility of an RNA-based NGS fusion panel for a wide variety of solid tumors in the appropriate clinicopathologic context. These findings warrant further validation in larger studies involving multiple institutional patient cohorts.
- 24 November 2023
- Published by Oxford University Press (OUP) in American Journal of Clinical Pathology
- Vol. 161 (4) , 329-341
Diagnostic impact of RNA-based next-generation sequencing fusion panel for solid tumors: A single-institution experience
Objectives: Gene rearrangements frequently act as oncogenic driver mutations and determine the onset and progression of cancer. RNA-based next-generation sequencing (NGS) is being used with increasing frequency for solid tumors. The purpose of our study is to investigate the feasibility and utility of an RNA-based NGS fusion panel for solid tumors. Methods: We conducted a retrospective, single-institution review of fusion panels requested between May 2022 and March 2023. Demographic, clinical, pathologic, and molecular findings of the patients were reviewed. The utility of the RNA-based NGS fusion panel for the pathologic diagnosis of solid tumors was assessed. Results: Our study included 345 cases, and a fusion event was identified in 24.3% (78/321) of cases. Among the 110 cases submitted for diagnostic purposes, a fusion event was detected in 42.7% (47/110) of cases. The results led to refinement or clarification of the initial diagnosis in 31.9% (15/47) of cases and agreement or support for the initial diagnosis in 59.6% (28/47) of cases. Furthermore, our study indicated that the overall cellularity (tumor and normal tissue) of the tested specimen influences the success of the testing process. Conclusions: In summary, this study demonstrated the feasibility and utility of an RNA-based NGS fusion panel for a wide variety of solid tumors in the appropriate clinicopathologic context. These findings warrant further validation in larger studies involving multiple institutional patient cohorts.